GlassScriptPhysician profile
Wikrom Karnsakul
NPI 1366522351
$22,608.76
in general payments reported to CMS, 2019-2025
9 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4.15 · 2022: $5,067 · 2023: $12K · 2024: $5,118 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $2,282 · Food and Beverage: $1,399 · Travel and Lodging: $1,213 · Education: $0.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,642.50 |
| Consulting Fee | $2,282.00 |
| Food and Beverage | $1,399.19 |
| Travel and Lodging | $1,213.15 |
| Education | $0.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $14,462.20 | 2023-2025 | Bylvay, Onivyde |
| Mirum Pharmaceuticals, INC. | $4,587.90 | 2022-2025 | Livmarli |
| Albireo Pharma, INC. | $2,069.30 | 2023 | Bylvay |
| Abbvie INC. | $1,342.83 | 2022-2024 | |
| Ipsen Pharma Sas | $74.99 | 2024 | Iqirvo |
| Qol Medical, LLC | $41.53 | 2024-2025 | Sucraid, Sucraid |
| Soleno Therapeutics, INC. | $25.04 | 2025 | Vykat Xr |
| Travere Therapeutics, INC. | $4.97 | 2019-2023 | Cholbam |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wikrom Karnsakul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.